Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2016 by Celgene Corporation
Information provided by (Responsible Party):
Celgene Corporation Identifier:
First received: March 27, 2012
Last updated: October 21, 2016
Last verified: October 2016
No Study Results Posted on for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: October 2021
  Estimated Primary Completion Date: October 2021 (Final data collection date for primary outcome measure)